The change of immune profiles and existence of circulating tumor cells following prostate cryotherapy may be correlated with the clinical outcome.

Inclusion Criteria:

• Age>20 years
• Histopathology-proven prostate adenocarcinoma
• Non-metastatic localized disease
• Subjects have chosen their curative, definitive treatments for prostate cancer prior to enrolling for the study
• Subjects are willing to sign the informed consent and agree to comply with the study procedures

Exclusion Criteria:

• Chronic use (> 2 weeks) of > 10 mg/day of prednisone or prednisolone within 2 months of the screening (topical or inhalational corticosteroids are permitted)
• Concurrent use of immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry
• Other conditions the investigators think may affect subjects' compliance

Taiwanese organ-confined or locally advanced prostate cancer patients